CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

References

• Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, van de Kasteele W, Rimmelzwaan GF, Haanen JB, Ovaa H, et al. Design and use of conditional MHC class I ligands. Nat Med 2006; 12:246-51; PMID:16462803; http://dx.doi.org/10.1038/nm1360
   PubMed Web of Science ®Google Scholar
• Van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013; 31:e439-42; PMID:24043743; http://dx.doi.org/10.1200/JCO.2012.47.7521
   PubMed Web of Science ®Google Scholar
• Linnemann C, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T cells in human melanoma. Nat Med 2015; 21:1-7; PMID:25569538; http://dx.doi.org/10.1038/nm.3785
   PubMedGoogle Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (80-.) 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081-91; PMID:22237626; http://dx.doi.org/10.1158/0008-5472.CAN-11-3722
   PubMed Web of Science ®Google Scholar
• Löwer M, Renard BY, de Graaf J, Wagner M, Paret C, Kneip C, Türeci O, Diken M, Britten C, Kreiter S, et al. Confidence-based Somatic Mutation Evaluation and Prioritization. PLoS Comput Biol 2012; 8:e1002714; PMID:23028300
   PubMedGoogle Scholar
• Castle JC, Loewer M, Boegel S, Tadmor AD, Boisguerin V, de Graaf J, Paret C, Diken M, Kreiter S, Türeci Ö, et al. Mutated tumor alleles are expressed according to their DNA frequency. Sci Rep 2014; 4:4743; PMID:24752137; http://dx.doi.org/10.1038/srep04743
   PubMed Web of Science ®Google Scholar
• Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Türeci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006; 108:4009-17; PMID:16940422; http://dx.doi.org/10.1182/blood-2006-04-015024
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, Huber C, Türeci O, Sahin U. Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals. J Immunol 2008; 180:309-18; PMID:18097032; http://dx.doi.org/10.4049/jimmunol.180.1.309
   PubMed Web of Science ®Google Scholar
• Kuhn A, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, Darzynkiewicz E, Huber C, Türeci O, Sahin U. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 2010; 17:961-71; PMID:20410931; http://dx.doi.org/10.1038/gt.2010.52
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010; 70:9031-40; PMID:21045153; http://dx.doi.org/10.1158/0008-5472.CAN-10-0699
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520:692-6; PMID:25901682; http://dx.doi.org/10.1038/nature14426
   PubMed Web of Science ®Google Scholar
• Ivics Z, Izsvak Z, Minter A, Hackett PB. Identification of functional domains and evolution of Tc1-like transposable elements. Proc Natl Acad Sci U S A 1996; 93:5008-13; PMID:8643520; http://dx.doi.org/10.1073/pnas.93.10.5008
   PubMed Web of Science ®Google Scholar
• Singh H, Huls H, Kebriaei P, Cooper L J N. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 2014; 257:181-90; PMID:24329797; http://dx.doi.org/10.1111/imr.12137
   PubMed Web of Science ®Google Scholar
• Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66:10995-1004; PMID:17108138; http://dx.doi.org/10.1158/0008-5472.CAN-06-0160
   PubMed Web of Science ®Google Scholar
• Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp 2013; e50070; PMID:23407473; http://dx.doi.org/10.3791/50070
   PubMedGoogle Scholar
• Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26:332-42; PMID:12843795; http://dx.doi.org/10.1097/00002371-200307000-00005
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233-40; PMID:19304471; http://dx.doi.org/10.1016/j.coi.2009.03.002
   PubMed Web of Science ®Google Scholar
• Baldan V, Griffiths R, Hawkins R, Gilham D. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br J Cancer 2015; 112:1510-8; PMID:25867267; http://dx.doi.org/10.1038/bjc.2015.96
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19:747-52; PMID:23644516; http://dx.doi.org/10.1038/nm.3161
   PubMed Web of Science ®Google Scholar
• Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, Ovaa H. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 2006; 1:1120-32; PMID:17406393; http://dx.doi.org/10.1038/nprot.2006.121
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
   PubMed Web of Science ®Google Scholar
• Kurts C, Heath WR, Carbone FR, Allison J, Miller JF, Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996; 184:923-30; PMID:9064352; http://dx.doi.org/10.1084/jem.184.3.923
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-3; PMID:9624005; http://dx.doi.org/10.1038/31002
   PubMed Web of Science ®Google Scholar
• Feau S, Arens R, Togher S, Schoenberger SP. Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat Immunol 2011; 12:908-13; PMID:21804558; http://dx.doi.org/10.1038/ni.2079
   PubMed Web of Science ®Google Scholar
• Feau S, Garcia Z, Arens R, Yagita H, Borst J, Schoenberger SP. The CD4+ T-cell help signal is transmitted from APC to CD8+ T-cells via CD27–CD70 interactions. Nat Commun 2012; 3:948; PMID:22781761; http://dx.doi.org/10.1038/ncomms1948
   PubMed Web of Science ®Google Scholar
• Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/jem.20050915
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice. Science (80-.). 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-09; PMID:25344738; http://dx.doi.org/10.1038/nm.3708
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Rao S, Yang H, Penninger JM, Kroemer G. Autophagy in non-small cell lung carcinogenesis: A positive regulator of antitumor immunosurveillance. Autophagy 2014; 10:529-31; PMID:24413089; http://dx.doi.org/10.4161/auto.27643
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 2014; 147:502-26; PMID:25043945; http://dx.doi.org/10.1053/j.gastro.2014.04.001
   PubMed Web of Science ®Google Scholar
• Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001; 98:13255-60; PMID:11687624; http://dx.doi.org/10.1073/pnas.231326898
   PubMed Web of Science ®Google Scholar
• Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M. Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers. Gastroenterology 2008; 134:988-97; PMID:18395080; http://dx.doi.org/10.1053/j.gastro.2008.01.015
   PubMed Web of Science ®Google Scholar
• Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun [electronic Resour. a J. Acad. Cancer Immunol. 2004; 4:14; PMID:15563124
   PubMedGoogle Scholar
• Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, et al. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunol Immunother 2015; 64(7):831-42; PMID:25863943; http://dx.doi.org/10.1007/s00262-015-1688-2
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107:13824-9; PMID:20631300; http://dx.doi.org/10.1073/pnas.1008051107
   PubMed Web of Science ®Google Scholar
• Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014; 344:1396-401; PMID:24925914; http://dx.doi.org/10.1126/science.1254257
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118:469-74; PMID:19554337; http://dx.doi.org/10.1007/s00401-009-0561-9
   PubMed Web of Science ®Google Scholar
• Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities. Cancer Discov 2013; 3:730-41; PMID:23796461; http://dx.doi.org/10.1158/2159-8290.CD-13-0083
   PubMed Web of Science ®Google Scholar
• Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015; 47:458-68; PMID:25848751; http://dx.doi.org/10.1038/ng.3273
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512:324-7; PMID:25043048; http://dx.doi.org/10.1038/nature13387
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell 2010; 141:52-67; PMID:20371345; http://dx.doi.org/10.1016/j.cell.2010.03.015
   PubMed Web of Science ®Google Scholar
• Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y. α v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med 2005; 202:61-72; PMID:15998788; http://dx.doi.org/10.1084/jem.20042138
   PubMed Web of Science ®Google Scholar
• Godefroy E, Manches O, Dréno B, Hochman T, Rolnitzky L, Labarrière N, Guilloux Y, Goldberg J, Jotereau F, Bhardwaj N. Matrix Metalloproteinase-2 Conditions Human Dendritic Cells to Prime Inflammatory TH2 Cells via an IL-12- and OX40L-Dependent Pathway. Cancer Cell 2011; 19:333-46; PMID:21397857; http://dx.doi.org/10.1016/j.ccr.2011.01.037
   PubMed Web of Science ®Google Scholar
• Godefroy E, Bhardwaj N. Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2. Oncoimmunology 2012; 1:109-11; PMID:22720227; http://dx.doi.org/10.4161/onci.1.1.17994
   PubMed Web of Science ®Google Scholar
• Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N, Saenger Y, Fu Y, Ravindran R, Pulendran B, et al. Activation of Toll-like Receptor-2 by Endogenous Matrix Metalloproteinase-2 Modulates Dendritic-Cell-Mediated Inflammatory Responses. Cell Rep 2014; 9:1856-70; PMID:25466255; http://dx.doi.org/10.1016/j.celrep.2014.10.067
   PubMed Web of Science ®Google Scholar
• Da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. Cancer Immunol Res 2014; 2:410-22; PMID:24795354; http://dx.doi.org/10.1158/2326-6066.CIR-13-0171
   PubMed Web of Science ®Google Scholar
• Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic In-Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case report, Hypothesis, and Clinical Trial. Cancer Immunol Res 2014; PMID:24801836; http://dx.doi.org/10.1158/2326-6066.CIR-14-0024
   PubMed Web of Science ®Google Scholar
• Cassier P, et al. CSF1R Inhibition with Emactuzumab in Locally Advanced Diffuse-type Tenosynovial Giant Cell Tumors of the soft tissue: a phase 1, dose escalation and expansion study. Lancet Oncol in press, 2015
   PubMed Web of Science ®Google Scholar
• Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014; 25:846-59; PMID:24898549; http://dx.doi.org/10.1016/j.ccr.2014.05.016
   PubMed Web of Science ®Google Scholar
• Timke C, Winnenthal HS, Klug F, Roeder FF, Bonertz A, Reissfelder C, Rochet N, Koch M, Tjaden C, Buechler MW, et al. Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer. BMC Cancer 2011; 11:134; http://dx.doi.org/10.1186/1471-2407-11-134
   PubMed Web of Science ®Google Scholar
• Reissfelder C, Stamova S, Gossmann C, Braun M, Bonertz A, Walliczek U, Grimm M, Rahbari NN, Koch M, Saadati M, et al. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest 2014; 125:739-51; PMID:25562322; http://dx.doi.org/10.1172/JCI74894
   PubMed Web of Science ®Google Scholar
• Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy. Cancer Cell 2013; 24:589-602; PMID:24209604; http://dx.doi.org/10.1016/j.ccr.2013.09.014
   PubMed Web of Science ®Google Scholar
• Khandelwal N, Breinig M, Speck T, Michels T, Kreutzer C, Sorrentino A, Sharma AK, Umansky L, Conrad H, Poschke I, et al. A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Mol Med 2015; 7(4):450-63
   PubMed Web of Science ®Google Scholar
• Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, Stieg MR, Grassmann S, Kobold S, Siveke JT, et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ 2014; 21:1825-37; PMID:25012502; http://dx.doi.org/10.1038/cdd.2014.96
   PubMed Web of Science ®Google Scholar
• Schnurr M, Duewell P. Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer. Oncoimmunology 2014; 3, e955687; PMID:25941620; http://dx.doi.org/10.4161/21624011.2014.955687
   PubMedGoogle Scholar
• Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; http://dx.doi.org/10.1056/NEJMoa1504030
   Web of Science ®Google Scholar
• Diken M, Attig S, Grunwitz C, Kranz L, Simon P, van de Roemer N, Vascotto F, Kreiter S. CIMT 2013: Advancing targeted therapies-report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany. Hum Vaccin Immunother 2013; 9:2025-32; PMID:23877042; http://dx.doi.org/10.4161/hv.25768
   PubMed Web of Science ®Google Scholar
• Houot R, Kohrt H. CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology 2014; 3, e941740; PMID:25610724; http://dx.doi.org/10.4161/21624011.2014.941740
   PubMedGoogle Scholar
• Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122:1066-75; PMID:22326955; http://dx.doi.org/10.1172/JCI61226
   PubMed Web of Science ®Google Scholar
• Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 1997; 3:682-5; PMID:9176498; http://dx.doi.org/10.1038/nm0697-682
   PubMed Web of Science ®Google Scholar
• Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, Louahed J, Chen W, Woods K, Cebon JS. MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells. Cancer Immunol Res 2014; 2:351-60; PMID:24764582; http://dx.doi.org/10.1158/2326-6066.CIR-13-0181
   PubMed Web of Science ®Google Scholar
• Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD1, PD-L1 and CTLA-4. Clin Cancer Res 2015; 21:1639-51; PMID:25589619; http://dx.doi.org/10.1158/1078-0432.CCR-14-2339
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81; PMID:25428507; http://dx.doi.org/10.1038/nature13988
   PubMed Web of Science ®Google Scholar
• Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014; 15:431-8; PMID:24658051; http://dx.doi.org/10.1038/ni.2850
   PubMed Web of Science ®Google Scholar
• Van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, Boon L, Smit VT, Welters MJ, Ossendorp F, et al. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin Cancer Res 2015; 21:781-94; PMID:25501579; http://dx.doi.org/10.1158/1078-0432.CCR-14-2142
   PubMed Web of Science ®Google Scholar
• Van der Sluis TC, Sluijter M, van Duikeren S, West BL, Melief CJ, Arens R, van der Burg SH, van Hall T. Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression. Cancer Immunol Res 2015; PMID:25888578; http://dx.doi.org/10.1158/2326-6066.CIR-15-0052
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383:816-27; PMID:24054424; http://dx.doi.org/10.1016/S0140-6736(13)60802-8
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65; PMID:22735384; http://dx.doi.org/10.1016/S0140-6736(12)60868-X
   PubMed Web of Science ®Google Scholar
• Robert C, et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2014; http://dx.doi.org/10.1056/NEJMoa1412690
   Web of Science ®Google Scholar
• Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 2014; 513:105-9; PMID:25079330; http://dx.doi.org/10.1038/nature13572
   PubMed Web of Science ®Google Scholar
• Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483:100-3; PMID:22281684; http://dx.doi.org/10.1038/nature10868
   PubMed Web of Science ®Google Scholar
• Hodi S, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol [Epub ahead of print] 2015; 33(17):1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 150419053123009 2015; 372(26):2521-32; http://dx.doi.org/10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16(5):522-30; http://dx.doi.org/10.1016/S1470-2045(15)70122-1
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48:218-25; PMID:22056637; http://dx.doi.org/10.1016/j.ejca.2011.09.028
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2014; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N Engl J Med 2015; 372:2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015; 33(18):2013-20; http://dx.doi.org/10.1200/JCO.2014.58.1041
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial [abstract]. J Clin Oncol 2015; 33:1430-7; PMID:25452452; http://dx.doi.org/10.1200/JCO.2014.59.0703
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med 2015; 372:2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Maio M, Robert C. Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. Semin Oncol 2015; 42:429-35; PMID:25965361; http://dx.doi.org/10.1053/j.seminoncol.2015.02.010
   PubMed Web of Science ®Google Scholar